Activity
NGeneBio launched NGS based breast cancer diagnostic service in Thailand
관리자
Launched NGS based breast cancer diagnostic service in a newly installed inspection laboratory of a Thai consignment inspection agency, MP Group.
Expand precision
diagnosis service and dominate the new market
Using NGeneBio’s
BRCAaccuTest™PLUS test to identify the BRCA gene which is related
to breast cancer and ovarian cancer. The BRCA test service provides -▲analyzes breast BRCA 1/2 gene mutation screening, ▲ an individual's innate breast cancer, ovarian cancer risk, ▲ family history to identify genetic characteristics, ▲and generates personalized gene reports.
NGeneBio
representatives also attended and presented the necessity of NGS precision
diagnosis and introduced steady seller products .
"Thailand has
the largest medical device market among ASEAN countries due to the government's
active support and investment in healthcare," said Choi Dae-chul of
NGeneBio . "As we have been asked to cooperate in research on genome
projects, we will make efforts to expand the Thai market and lead the NGS
precision diagnosis market in Southeast Asia."
"BRCAaccuTest PLUS is certified by FDA
Thailand, It can be used not only as a diagnostic test for breast cancer target
treatment but also as a test for mutation screening of BRCA1/2 genes,"
Rittichai Srivijarn of MP Group Chairman said. “Based on a friendly
relationship with NGeneBio, we plans to expand the BRCA service as well as
massively increase the number of joint projects.”
